4//SEC Filing
Lilja Anders 4
Accession 0001104659-20-007181
CIK 0001760542other
Filed
Jan 26, 7:00 PM ET
Accepted
Jan 27, 4:52 PM ET
Size
13.9 KB
Accession
0001104659-20-007181
Insider Transaction Report
Form 4
Lilja Anders
Sr. VP, Technical Development
Transactions
- Sale
Common Stock
2020-01-23$12.81/sh−7,568$96,932→ 0 total - Exercise/Conversion
Common Stock
2020-01-23$0.10/sh+4,075$408→ 4,075 total - Sale
Common Stock
2020-01-23$12.17/sh−4,075$49,601→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-23−4,075→ 0 totalExercise: $0.10Exp: 2026-12-31→ Common Stock (4,075 underlying) - Exercise/Conversion
Common Stock
2020-01-23$0.10/sh+7,568$757→ 7,568 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-23−7,568→ 13,098 totalExercise: $0.10Exp: 2026-12-31→ Common Stock (7,568 underlying)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.6265 to $12.9584, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]This option is fully vested and exercisable.
- [F3]25% of this option vested and became exercisable on January 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter.
Documents
Issuer
HOOKIPA Pharma Inc.
CIK 0001760542
Entity typeother
Related Parties
1- filerCIK 0001768216
Filing Metadata
- Form type
- 4
- Filed
- Jan 26, 7:00 PM ET
- Accepted
- Jan 27, 4:52 PM ET
- Size
- 13.9 KB